Related Experiment Videos
[Cardioprotective and cardio-reparative drugs]
1Unidad de Cardiología, Hospital General de Igualada, Barcelona.
Insights
Left ventricular hypertrophy, a consequence of arterial hypertension, has two components: hemodynamic and neuro-hormonal. Antihypertensive treatments can improve outcomes by addressing these factors, offering cardio-protection and cardio-reparation.
Area of Science:
- Cardiology
- Hypertension Research
- Fibrosis Studies
Context:
- Arterial hypertension is a major risk factor for cardiovascular disease.
- Left ventricular hypertrophy (LVH) is a significant consequence of uncontrolled hypertension.
- LVH contributes to increased morbidity and mortality.
Purpose:
- To elucidate the dual components of left ventricular hypertrophy (LVH) in arterial hypertension.
- To discuss the therapeutic implications of targeting both hemodynamic and neuro-hormonal pathways in LVH.
- To highlight the role of ACE inhibitors in reversing fibrotic changes and improving hypertensive syndrome.
Summary:
- Left ventricular hypertrophy (LVH) presents with a myocytic component driven by hemodynamic factors, responsive to various antihypertensive therapies, leading to cardio-protection.
- A distinct fibrotic component of LVH, originating from neuro-hormonal influences, is amenable to reversal, particularly with Angiotensin-Converting Enzyme Inhibitors (ACEIs).
- ACEIs demonstrate potential for cardio-reparation by targeting the fibrotic aspect of LVH and improving overall hypertensive syndrome components.
Impact:
- Demonstrates that antihypertensive interventions can improve cardiovascular outcomes by addressing LVH.
- Highlights the specific role of ACE inhibitors in reversing cardiac fibrosis, a key aspect of LVH.
- Provides a framework for understanding LVH as a potentially reversible condition, improving hypertensive syndrome management.
Abstract:
The left ventricular hypertrophy is a deleterious consequence of the arterial hypertension, recognized as independent risk factor. The left ventricular hypertrophy has a myocytic component, of hemodynamic origin, where all the antihypertensive treatments known would be active, in greater or smaller degree, and it's been demonstrated the benefit of the intervention in the sense of the fact that exist improvement indications of the morbi-mortality (cardio-protection). The left ventricular hypertrophy has at the same time a fibrotic component, of neuro-hormonal origin that can be reversed (cardio-reparation) fundamentally by influence of the ACEIs, that would improve furthermore all the components of the called "hypertensive syndrome".